Did Sppi get FDA approval?
Did Sppi get FDA approval?
–(BUSINESS WIRE)– Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. Food and Drug Administration (FDA) has granted Accelerated Approval of Beleodaq™ for the …
Is Spectrum Pharmaceuticals a good company?
Spectrum Pharmaceuticals has received a consensus rating of Buy. The company’s average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.
Did Rolontis get approved?
Rolontis obtained the Ministry of Food and Drug Safety’s approval in March, becoming Hanmi’s first biologic drug and the nation’s 33rd novel drug.
Who is spectrum pharmaceuticals?
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in hematology and oncology. Spectrum has a strong track record for in-licensing and acquiring differentiated drugs, and for clinical development.
Who owns SPPI stock?
Top 10 Owners of Spectrum Pharmaceuticals Inc
| Stockholder | Stake | Shares owned |
|---|---|---|
| Armistice Capital LLC | 9.65% | 17,100,000 |
| BlackRock Fund Advisors | 7.24% | 12,817,131 |
| D. E. Shaw & Co. LP | 4.43% | 7,845,726 |
| The Vanguard Group, Inc. | 4.32% | 7,646,403 |
Why is SPPI stock dropping?
The big decline came after the company announced that the U.S. Food and Drug Administration turned down approval of Rolontis in treating neutropenia in patients receiving cancer drugs that decrease bone marrow activity.
Why is Spectrum Pharmaceuticals stock dropping?
Will Spectrum Pharmaceuticals stock go up?
The 5 analysts offering 12-month price forecasts for Spectrum Pharmaceuticals Inc have a median target of 4.00, with a high estimate of 10.00 and a low estimate of 3.00. The median estimate represents a +387.21% increase from the last price of 0.82.
What drugs does Spectrum Pharmaceuticals make?
Approved drugs Folotyn (pralatrexate) is an antifolate drug marketed for relapsed or refractory peripheral T-cell lymphoma. Khapzory (levoleucovorin) (Disodium Levoleucovorin), for injection, a folate analog for three indications: Rescue after high-dose methotrexate therapy in patients with osteosarcoma.
Will Sppi go back up?
On average, analysts forecast that SPPI’s EPS will be -$0.55 for 2022, with the lowest EPS forecast at -$0.71, and the highest EPS forecast at -$0.37. On average, analysts forecast that SPPI’s EPS will be -$0.07 for 2023, with the lowest EPS forecast at -$0.28, and the highest EPS forecast at $0.06.